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Background:  Directive  2004/24/EC,  which  came  into  force  in  2011, created  new  regulatory  requirements
for  traditional  herbal  medicines  (THM).  This  study  compared  the  Spanish  THM  registry  before  and  after
the Directive  came  fully  into  force  in  2011.
Methods: We  consulted  the  herbal  medicinal  plant  and  drug  catalogues  (General  Council  of  the  Ofﬁcial
Colleges  of  Pharmacists),  the  website  of  the  European  Medicines  Agency  (EMA),  and  retail  web  sites.
Results:  Of  315  THM  (from  39 companies)  licensed  in Spain  in 2010,  only  48  (10  companies)  remained
licensed  in 2013,  mainly  due  to their  withdrawal:  the EMA  had  received  just  123 applications  from  Spain
and at  least  34%  formerly  licensed  THM  had  shifted  to the  less  strictly  regulated  food  sector,  while  up
to  54%  might  have  disappeared  from  the  market.  However,  there  is  still  a signiﬁcant  presence  of  retail
websites  making  illegal  health  claims.
Conclusion:  In Spain,  the  public  health  beneﬁts  of  the  Directive  2004/24/EC  might  be  less  than  expected.
© 2014  SESPAS.  Published  by  Elsevier  España,  S.L.U.  All rights  reserved.
Efecto  en  Espan˜a  de  la  directiva  Europea  de  uso  tradicional  sobre  el  registro  de
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Antecedentes:  En  2011  entró  totalmente  en  vigor  la  Directiva  2004/24/CE,  que  impone  nuevos  requerim-
ientos  a los  medicamentos  tradicionales  a  base  de plantas.  Este  trabajo  analiza  el efecto  sobre  su  registro
en Espan˜a.
Métodos:  Se consultaron  los  catálogos  de  plantas  medicinales  y de  medicamentos  (CGCOF),  la página  web
de la  Agencia  Europea  del Medicamento  (EMA)  y sitios  de  venta  en  Internet.
Resultados:  De  los  315  medicamentos  a base  de  plantas  autorizados  en  2010,  procedentes  de
39  compan˜ías;  solo  quedaban  48  (10 compan˜ías)  en  2013  por renuncia  de  la  mayoría:  sólo  123 solici-
tudes  fueron  recibidas  a la EMA  y al  menos  un  34% se pasó  al sector  de  alimentación  (menos  estrictamente
regulado).  Hasta  un  54%  podría  no comercializarse  actualmente.  Sin  embargo,  existe  una presencia  sig-
niﬁcativa de  sitios  web  anunciando  ilegalmente  propiedades  saludables  para sus  productos.
Conclusión:  Los  beneﬁcios  de  la Directiva  2004/24/CE  para  la salud  pública  espan˜ola  podrían  ser  menos
de  los  esperados.
©  2014  SESPAS.  Publicado  por  Elsevier  España,  S.L.U.  Todos  los  derechos  reservados.ntroduction
Ten years ago, the Directive 2004/24/EC (the Directive) estab-
ished a regulatory framework for traditional herbal medicinal
roducts. The Directive, which came fully into force in Spain on 1
ay  2011, requires these products to meet speciﬁc and appropriate
tandards of efﬁcacy, safety and quality to protect public health1.
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edicina. Universidad de Alcalá Alcalá de Henares (Madrid). Spain.
el.: +34918854515; fax: +34918854590.
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http://dx.doi.org/10.1016/j.gaceta.2015.01.013
213-9111/© 2014 SESPAS. Published by Elsevier España, S.L.U. All rights reserved.In order to simplify the nomenclature, we will use along this arti-
cle the term “Traditional Medicines” (TM) to refer to both the old
and the current licensing categories of traditional herbal medicinal
products.
The Directive provides for a special simpliﬁed registration pro-
cedure for TM.  But actually it creates signiﬁcant new regulatory
requirements because manufacturers have to prove that their prod-
ucts have been made to strict standards of safety and quality. The
resulting new costs to manufacturers might result in loss of the
commercial viability of individual TM so that there might be fewer
TM on the market and a smaller range. This work compares the
register of TM in Spain before and after the Directive came fully
into force in 2011.
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tigure 1. Impact of the Directive 2004/24/EC, which came into force in 2011, on the
panish market of traditional medicines.
ethods
We  studied the effect of the Directive on the register of TM in
pain by comparing the number of TM licensed under either the
ormer legislation (years 2005, 2006 and 2010) or the Directive
years 2011, 2012 and 2013). These data were obtained respectively
rom the catalogues of Medicinal Plants2–4 and Drug and Medici-
al Products (Botplus version)5 published by the General Council of
fﬁcial Colleges of Pharmacists. Two researchers (from NTG, CGP,
NA and JBE) extracted data independently from each annual cat-
logue. The extracted data were cross-checked by the authors, and
ny discrepancy was resolved by discussion with a third author
FJLC).
The data of 2011 and 2013 on Traditional Use Registrations from
he European Medicines Agency (EMA)6,7 were analyzed by two
esearchers (CGP and JBE) in order to make an estimate of the
umber of former TM which refused to apply for a marketing autho-
isation under the Directive. In this connection, a further study was
ndertaken for making an estimate of their possible commercial-
zation in the food market through i) searching in the catalogues of
he General Council of Ofﬁcial Colleges of Pharmacists5, ii) enquir-
ng to the manufacturing laboratories and iii) searching the Internet
sing Yahoo and Google search engines and entering the search
erm “comprar planta medicinal” (“to buy medicinal plant”). The
panish retail sites found were analyzed for the commercialization
f former TM.
Since we detected on the Internet illegal health claims, we
onducted a second search aimed to make a preliminary evalua-
ion of the magnitude of the problem. We  entered “to buy herbal
edicine”, both in English and Spanish and, from the ﬁrst 500 con-
ecutive retail sites found, we selected the ones whose products
ould be bought from Spain. Then, they were evaluated for illegal
ealth indications.
The two searches on the Internet were conducted in 2013, from
ctober to December, and each web site was analyzed indepen-
ently by two authors (from NTG, CGP, ENA, JBE, AMM  and FJLC).
n case of conﬂicting reports on the evaluation of health or ther-
peutic claims, the ﬁnal decision was taken by the whole author
eam.
esults
Fig. 1 shows the evolution of the Spanish market of TM between
005 and 2013. The number of licensed TM diminished from
24 in 2005 to 315 in 2010, while there was no change in the
umber of producing companies (39). But these numbers sharply
ropped immediately after the Directive fully came into force, so
hat in 2011 there were only 38 granted TM (i.e. 12% out of 315nit. 2015;29(3):221–223
TM)  and they were produced by just 7 companies. This was mainly
due to the fact that the producing companies refused to apply for
the required marketing authorisations, since ii) the EMA  had only
received 123 applications for traditional use registration from Spain
by December 2013 and ii) at least 34% formerly licensed TM in 2010
(i.e. 108 out of 315 TM)  was  instead registered as food or food sup-
plement in 2013 and up to 54% might have disappeared from the
market (we  were unable to determine their status).
In 2013, only 48 TM (from 10 producing companies) had been
granted a license through the simpliﬁed registration procedure
(Figure 1), so that Spain accounted for just 6.14% of the 1319
authorized TM in the EU. The market was monopolized by a sin-
gle company, Arkopharma, that owned 72% of all TM in Spain. The
licensed TM were mainly used in the treatment of digestive or
metabolic disorders (10 TM), cardiovascular (10 TM)  and central
nervous system disorders (7 TM).
Finally, search on the Internet identiﬁed 63 retail sites making
illegal health or disease claims and whose products could be bought
from Spain.
Discussion
Our results clearly indicate that the simpliﬁed registration for
TM is actually a very exigent procedure so that, only 12% formerly
licensed TM in Spain had been granted a license in 2011 under
the Directive. As regard the producing companies, they have also
suffered the same “mass extinction” than TM upon the “Directive
impact” on the Spanish market. Furthermore, at least 34% formerly
licensed TM are now marketed as food or food supplements and
we have been unable to conﬁrm that more than a half of them are
currently commercialized. By contrast, the implementation of the
Directive in Germany resulted in the licensing of 45% former TM8.
Our data suggest that the Directive has triggered in Spain the
massive shift of herbal medicines into the less strictly regulated
food sector. We  have not addressed the causes behind the strong
effect of the Directive in the Spanish TM market. However, accord-
ing to a survey, only one third (36.6%) of the Spanish consumers
of herbal products used to treat health conditions buy them at
pharmacies9. In other European Countries as Germany, this ﬁg-
ure is almost inverse10. Therefore, if herbal products traditionally
used to treat health conditions are mainly bought in shops for
herbal products rather than in pharmacies, why should the pro-
ducing companies apply for a much more expensive traditional use
registration?
The shift of TM into the food sector in Spain may  have important
consequences as people determined to keep taking their favourite
unlicensed herbal medicines may  go online and choose to buy them
from merchants who may  be careless about quality or potency:
in a recent review of 13 common herbals of the top 50 Web
sites, only 10.5% recommended consultation with a healthcare pro-
fessional and fewer than 8% of retail sites provided information
regarding potential adverse effects, drug interactions, and other
safety information11. Even worse: we have found more than 60
websites advertising herbal medicinal products under illegal ther-
apeutic claims. Similar results were published recently in a report
on food supplement brands traded over the Internet in Spain12.
These facts somehow subvert the purpose of the Directive, which
was aimed at ensuring protection for public health through well
established standards of quality, safety and patient information.
In summary, the Directive has brought about a dramatic drop
in the number of licensed TM in Spain in favour of their marketing
in the food sector. The expected beneﬁts of the Directive to the
Spanish public health might be compromised, particularly by the
Internet marketing of herbal products with illegal health claims.
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What is already known about this subject?
The Directive 2004/24/E pursues, through the strict regula-
tion of herbal medicinal products, a high level of consumer
protection in the EU. However, it contains major burdens for
applicants often connected with high monetary costs.
What does this paper add?
Almost 90% formerly licensed traditional herbal medicines
are no longer licensed in Spain and there has been an impor-
tant shift into the food sector. This means that they are no
longer subject to the strict pre- and post-market control of the
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11. Owens C, Baergen R, Puckett D. Online sources of herbal product information.
Am  J Med. 2014;127:109–15.
12. CEACCU: La Publicidad y el Etiquetado en los Complementos Alimenticios.
¿Cumplen con la legislación?; [consulted on 22/5/2013]. Available at: http://medicinal products, which clearly subverts the purpose of the
Directive.
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